Related Experiment Video
Updated: Jun 18, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Lessons in hypertension from new clinical trials
1University of Texas Southwestern Medical Center, Dallas, TX 75390-8586, USA. shawna.nesbitt@utsouthwestern.edu
Hypertension often coexists with obesity and diabetes, yet remains undertreated. Early organ damage can occur even at high-normal blood pressure, highlighting the need for comprehensive risk assessment and timely intervention.
Area of Science:
- Cardiology
- Epidemiology
- Nephrology
Background:
- Hypertension frequently coexists with other cardiovascular risk factors like obesity and diabetes.
- A significant proportion of hypertension cases remain undertreated in clinical practice.
- Early organ damage may occur at blood pressure levels previously considered normal, especially in patients with multiple risk factors.
Purpose of the Study:
- To summarize key findings from recent epidemiologic and clinical studies on hypertension.
- To emphasize the importance of evaluating global cardiovascular risk.
- To discuss the role of renin-angiotensin system blockers in managing hypertension with comorbidities.
Main Methods:
- Review of recent epidemiologic and clinical studies.
- Analysis of current treatment guidelines and clinical trial data.
- Focus on patient populations with hypertension, obesity, diabetes, and chronic kidney disease.
Main Results:
- Hypertension is often associated with other cardiovascular risk factors.
- Hypertension is frequently undertreated.
- Early organ damage can manifest at high-normal blood pressure in at-risk individuals.
- Renin-angiotensin system blockers show efficacy in patients with type 2 diabetes and chronic kidney disease.
Conclusions:
- A global risk assessment approach is crucial for identifying individuals who will benefit most from antihypertensive therapy.
- Current US treatment guidelines are evolving to incorporate comprehensive risk evaluation.
- Pharmacologic agents like renin-angiotensin system blockers are valuable for managing complex hypertension cases involving diabetes and kidney disease.
Related Concept Videos
Hypertension III: Clinical Manifestations and Diagnostic Studies
Hypertension V: Nursing Management
Hypertension IV: Drug Therapy and Lifestyle Modifications
Hypertension II: Pathophysiology
Hypertension I: Introduction
Hypertension and Regulation of Blood Pressure